STOCK TITAN

Major Firefly Neuroscience (AIFF) investor trims stake in exit 13D/A

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Firefly Neuroscience, Inc. shareholder group files an exit Schedule 13D amendment after selling stock. A group including Windsor Private Capital LP, WPC entities, Jordan Kupinsky, HJRK Holdings, Rocco Marcello and John Cundari sold an aggregate of 147,300 common shares between December 31, 2025 and January 30, 2026.

After these open-market sales, Windsor-related entities each report beneficial ownership of 605,421 common shares, or 4.5% of Firefly Neuroscience’s 13,492,928 shares outstanding as of December 2, 2025. Jordan Kupinsky reports 674,181 shares, or 5.0%, including holdings through Windsor and HJRK Holdings. The group states it has ceased to be beneficial owner of more than 5% of the company’s common stock.

Positive

  • None.

Negative

  • None.

Insights

A prior 5%+ holder group reduced its Firefly Neuroscience stake and filed an exit 13D/A.

The filing shows a coordinated reporting group, led by Windsor Private Capital LP and related entities and individuals, disposing of 147,300 Firefly Neuroscience common shares in a series of open-market sales in early 2026. These transactions lowered their collective beneficial ownership.

Post-sales, Windsor-linked entities each report 605,421 shares, or 4.5% of the 13,492,928 Firefly shares outstanding as of December 2, 2025, while Jordan Kupinsky reports 674,181 shares, or 5.0%. The group explicitly characterizes this amendment as an exit filing, indicating it no longer holds more than 5% as a group.

This development mainly affects ownership transparency rather than company operations. Future company filings may show whether other investors increase positions as this shareholder group steps back from a previously larger stake.






If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to Rows 8, 10 and 11 above, this amount includes 605,421 shares of common stock ("Common Shares") of Firefly Neurosciences, Inc. (the "Issuer") held by Windsor Private Capital LP. In reference to Row 13 above, percentage ownership is based on 13,492,928 Common Shares of the Issuer outstanding as of December 2, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to Rows 8, 10 and 11 above, this amount includes 605,421 Common Shares of the Issuer held by Windsor Private Capital LP. In reference to Row 13 above, percentage ownership is based on 13,492,928 Common Shares of the Issuer outstanding as of December 2, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to Rows 8, 10 and 11 above, this amount includes 605,421 Common Shares of the Issuer. In reference to Row 13 above, percentage ownership is based on 13,492,928 Common Shares of the Issuer outstanding as of December 2, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to Rows 8, 10 and 11 above, this amount includes 605,421 Common Shares of the Issuer held by Windsor Private Capital LP, and 68,760 Common Shares held by HJRK Holdings Inc. In reference to Row 13 above, percentage ownership is based on 13,492,928 Common Shares of the Issuer outstanding as of December 2, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to Row 13 above, percentage ownership is based on 13,492,928 Common Shares of the Issuer outstanding as of December 2, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to Rows 8, 10 and 11 above, this amount includes 605,421 Common Shares of the Issuer held by Windsor Private Capital LP. In reference to Row 13 above, percentage ownership is based on 13,492,928 Common Shares of the Issuer outstanding as of December 2, 2025.


SCHEDULE 13D




Comment for Type of Reporting Person:
In reference to Rows 8, 10 and 11 above, this amount includes 605,421 Common Shares of the Issuer held by Windsor Private Capital LP. In reference to Row 13 above, percentage ownership is based on 13,492,928 Common Shares of the Issuer outstanding as of December 2, 2025.


SCHEDULE 13D


WPC Management Services Inc.
Signature:/s/ John Cundari
Name/Title:John Cundari, Partner
Date:01/30/2026
WPC GP I Inc.
Signature:/s/ John Cundari
Name/Title:John Cundari, Partner
Date:01/30/2026
Windsor Private Capital LP
Signature:/s/ John Cundari
Name/Title:John Cundari, Partner, WPC GP I Inc., as general partner of Windsor Private Capital LP
Date:01/30/2026
Jordan Kupinsky
Signature:/s/ JORDAN KUPINSKY
Name/Title:JORDAN KUPINSKY
Date:01/30/2026
HJRK Holdings Inc.
Signature:/s/ Jordan Kupinsky
Name/Title:Jordan Kupinsky, President and Director
Date:01/30/2026
Rocco Marcello
Signature:/s/ ROCCO MARCELLO
Name/Title:ROCCO MARCELLO
Date:01/30/2026
John Cundari
Signature:/s/ JOHN CUNDARI
Name/Title:JOHN CUNDARI
Date:01/30/2026

FAQ

What does the Firefly Neuroscience (AIFF) Schedule 13D/A Amendment No. 6 report?

The amendment reports that a group led by Windsor Private Capital LP reduced its Firefly Neuroscience holdings. After selling 147,300 common shares in open-market transactions, the group states it has ceased to be the beneficial owner of more than 5% of the company’s outstanding common stock.

How many Firefly Neuroscience (AIFF) shares did the reporting group sell?

The reporting group sold an aggregate of 147,300 Firefly Neuroscience common shares. These sales occurred in multiple open-market transactions between December 31, 2025 and January 30, 2026, at per-share prices generally around one dollar, as detailed individually in Item 5(c) of the filing.

What is Windsor Private Capital LP’s remaining ownership in Firefly Neuroscience (AIFF)?

Windsor Private Capital LP and related WPC entities each report beneficial ownership of 605,421 Firefly Neuroscience common shares. This represents 4.5% of the 13,492,928 common shares outstanding as of December 2, 2025, according to the percentages disclosed on their respective cover pages.

What is Jordan Kupinsky’s reported stake in Firefly Neuroscience (AIFF)?

Jordan Kupinsky reports beneficial ownership of 674,181 Firefly Neuroscience common shares, equal to 5.0% of shares outstanding. This total includes 605,421 shares held by Windsor Private Capital LP and 68,760 shares held by HJRK Holdings Inc., as described in the ownership footnote language.

Why is Amendment No. 6 characterized as an exit filing for Firefly Neuroscience (AIFF)?

The amendment is an exit filing because, after selling 147,300 shares, the reporting persons collectively ceased being beneficial owners of more than 5% of Firefly’s common stock. Crossing below the 5% threshold triggers a final Schedule 13D amendment to update public ownership records.

Over what period did Firefly Neuroscience (AIFF) share sales by Windsor occur?

Windsor’s Firefly Neuroscience share sales occurred between January 2, 2026 and January 30, 2026. The filing lists individual trades on multiple trading days, including blocks such as 25,000 shares at $1.0660 and 14,800 shares at $1.1095 per share, among numerous smaller transactions.
Firefly Neuroscience Inc.

NASDAQ:AIFF

AIFF Rankings

AIFF Latest News

AIFF Latest SEC Filings

AIFF Stock Data

11.55M
9.70M
38.52%
10.85%
13.28%
Software - Application
Services-prepackaged Software
Link
United States
KENMORE